VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
CVRX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
CVRXCVRx, Inc.
$0.61$16M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
CVRX logo

CVRx, Inc.

CVRX
NASDAQ · Medical Devices
$0.61
At close - Nov 17, 4:00 PM EST - USD
Market Cap$16M
P/E-0.3x
52W High$10.28
Volume637.26K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q1

Commercial Scaling Friction Challenges CVRx Financial Sustainability

CVRx faces a critical inflection point as revenue growth has decelerated to 19.6% in 2026Q1, struggling to convert its 87.2% gross margin into operational profitability.

GrowthDecelerating
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

CVRX price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

4/12 Beats

EPS beat 4 of last 12 quarters

02

Valuation risk

-101% Peers

P/E is 101% below peer median

03

Market leadership

RS 2 · Lag

Laggard (Underperforming 98% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 5

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
CVRX-91.39%
S&P 500 (^GSPC)+7.21%
1-Year Return
CVRX-93.42%
S&P 500 (^GSPC)+10.03%
3-Year Return
CVRX-96.55%
S&P 500 (^GSPC)+63.58%
5-Year Return
CVRX-95.93%
S&P 500 (^GSPC)+62.00%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$57M+10.4% YoY
Net income FY25
-$53M+11.1% YoY
Free cash flow FY25
-$41M-0.6% YoY
Operating margin FY25
-90.5%+25.5 pts YoY
ROIC (FY25)-256.7%
Avg ROIC 5Y-349.1%
ROE (TTM)-208.4%
Piotroski Score4 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate4/12 (33%)
Revenue Beat Rate7/12 (58%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 5, 2026
-$0.52-4.9%
vs -$0.50
$14M-0.7%
vs $14M
Q3 2026
Aug 6, 2026
-$0.53-1.0%
vs -$0.52
$16M+1.0%
vs $16M
Q2 2026
May 11, 2026
-$0.50+2.0%
vs -$0.51
$15M+1.9%
vs $14M
Q1 2026
Feb 12, 2026
-$0.46-9.5%
vs -$0.42
$16M+1.6%
vs $16M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Seeking Alpha·Nov 6, 2026
CVRx, Inc. (CVRX) Q3 2026 Earnings Call Transcript

CVRx, Inc. ( CVRX ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Kevin Hykes - President, CEO & Director John Landry - Chief Financial Officer Jared Oasheim - Consultant Conference Call Participants Mark Klausner - ICR Capital LLC Max Kruszeski - William Blair & Company L.L.C., Research Division Nick Mattiacci Presentation Operator Greetings.

Zacks Investment Research·Nov 5, 2026
CVRx (CVRX) Reports Q3 Loss, Lags Revenue Estimates

CVRx (CVRX) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $0.49 per share a year ago.

Zacks Investment Research·Nov 5, 2026
Here's What Key Metrics Tell Us About CVRx (CVRX) Q3 Earnings

While the top- and bottom-line numbers for CVRx (CVRX) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

GlobeNewsWire·Nov 5, 2026
CVRx Reports Third Quarter 2026 Financial and Operating Results

MINNEAPOLIS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the third quarter of 2026.  Recent Highlights  Total revenue for the third quarter of 2026 was $13.8 million U.S. revenue for the third quarter of 2026 was $13.0 million Active implanting centers in the U.S. increased to 262 as of September 30, 2026, as compared to 250 as of September 30, 2025 A second major Medicare Advantage provider has issued a coverage policy for Barostim, effective July 17, 2026, covering the current FDA-approved indication and patients enrolled in BENEFIT-HF.

Filtered for CVRx, Inc.More Headlines
04

Compare before deciding

Benchmark CVRX against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for CVRx, Inc. (CVRX)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
CVRX logoCVRXCVRx, Inc.Current
$0.61$16.21M-0.3110.45%-88.28%-208.45%—
LIVN logoLIVNLivaNova PLC
$91.92$5.05B26.9110.74%13.01%15.35%—
NVCR logoNVCRNovocure Ltd
$11.14$1.29B-10.698.28%-16.78%-35.81%—
LFST logoLFSTLifeStance Health Group, Inc.
$14.17$5.5B77.0913.85%4.29%4.82%—
MDT logoMDTMedtronic plc
$102.32$131.37B25.148.43%13.93%10.51%2.76%
ABT logoABTAbbott Laboratories
$104.71$182.38B38.715.67%9.75%9%2.25%

Compare CVRX vs Peers

CVRx, Inc. (CVRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs LIVN

Most directly comparable listed peer for CVRX.

Scale Benchmark

vs ABT

Larger-name benchmark to compare CVRX against a more recognizable public peer.

Peer Set

Compare Top 5

vs LIVN, NVCR, LFST, MDT

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

CVRX SEC Filings & Documents

CVRx, Inc. (CVRX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 6, 2026·SEC

Material company update

Jun 9, 2026·SEC

Material company update

May 11, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 13, 2026·SEC

FY 2025

Feb 18, 2025·SEC

FY 2024

Feb 9, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 6, 2026·SEC

FY 2026

May 12, 2026·SEC

FY 2025

Nov 6, 2025·SEC

Get notified when CVRX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

CVRX Frequently Asked Questions

CVRx, Inc. (CVRX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is CVRx, Inc.'s revenue?

CVRx, Inc. (CVRX) reported $60.3M in revenue over the trailing twelve months. Revenue was $56.7M in fiscal year 2025. That is 805% more than the $6.3M of fiscal year 2019.

How fast is CVRx, Inc. growing?

CVRx, Inc. (CVRX) grew revenue by 7.8% over the trailing twelve months, compared with the twelve months before.

Is CVRX profitable?

No. CVRx, Inc. (CVRX) reported a net loss of $53.3M over the trailing twelve months.

Dividend & Returns
What is CVRX's return on equity?

CVRx, Inc. (CVRX) had a return on equity (ROE) of -208.4% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is CVRx, Inc.'s free cash flow?

CVRx, Inc. (CVRX) had negative free cash flow of $42.0M over the trailing twelve months.

What if you invested $1,000 in CVRX back in 2019?

Total return calculator · dividends reinvested · 7+ years of data

See returns →